Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines

Hepatology

Volumn 46, Issue 1, 2007, Pages 66-73

  Cua, Ian Homer Y ^a   Hui, Jason M ^b   Bandara, Priyanka ^a   Kench, James G ^a   Farrell, Geoffrey C ^c   McCaughan, Geoffrey W ^d   George, Jacob ^a,e  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c The Australian National University   (Australia)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^e WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; LEPTIN;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE ASSOCIATION; FATTY LIVER; GENOTYPE; HEPATITIS C; HUMAN; INSULIN RESISTANCE; LIVER FIBROSIS; LIVER INJURY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ADIPONECTIN; ADULT; BIOPSY; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INSULIN RESISTANCE; INTERLEUKIN-6; LEPTIN; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PATIENT SELECTION; REFERENCE VALUES; TUMOR NECROSIS FACTOR-ALPHA; VIRAL LOAD;

EID: 34547444610     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21703     Document Type: Article

References (50)

1. Hui JM, Kench J, Farrell GC, Lin R, Samarasinghe D, Liddle C, et al. Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. J Gastroenterol Hepatol 2002;17:873-881.
2. Kumar D, Farrell GC, Fung C, George J. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response. HEPATOLOGY 2002;36:1266-1272.
3. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. HEPATOLOGY2001;33:1358-1364.
4. Rubbia-Brandt L, Fabris P, Paganin S, Leandro G, Male PJ, Giostra E, et al. Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut 2004;53:406-412.
5. Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. HEPATOLOGY 2003;38:75-85.
6. Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology 2003;125:1695-1704.
7. Aytug S, Reich D, Sapiro LE, Bernstein D, Begum N. Impaired IRS-1/ PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. HEPATOLOGY 2003;38:1384-1392.
8. Kawaguchi T, Yoshida T, Harada M, Hisamoto T, Nagao Y, Ide T, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004;165:1499-1508.
9. Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004;126:840-848.
10. Petit JM, Bour JB, Galland-Jos C, Minello A, Verges B, Guiguet M, et al. Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol 2001;35:279-283.
11. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
12. Sud A, Hui JM, Farrell GC, Bandara P, Kench JG, Fung C, et al. Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. HEPATOLOGY 2004;39:1239-1247.
13. Muzzi A, Leandro G, Rubbia-Brandt L, James R, Keiser O, Malinverni R, et al. Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients. J Hepatol 2005;42:41-46.
14. D'Souza R, Sabin CA, Foster GR. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol 2005;100:1509-1515.
15. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, Salmeron J, Diago M, Fernandez-Rodriguez CM, et al. Insulin resistance impairs sustained tesponse rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005;128:636-641.
16. Pittas AG, Joseph NA, Greenberg AS. Adipocytokines and insulin resistance. J Clin Endocrinol Metab 2004;89:447-452.
17. Vettor R, Milan G, Rossato M, Federspil G. Review article: adipocytokines and insulin resistance. Aliment Pharmacol Ther 2005;22 Suppl 2:3-10.
18. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005;42:987-1000.
19. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003;112:91-100.
20. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001;103:1057-1063.
21. Kamada Y, Tamura S, Kiso S, Matsumoto H, Saji Y, Yoshida Y, et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 2003;125:1796-1807.
22. Chalasani N, Crabb DW, Cummings OW, Kwo PY, Asghar A, Pandya PK, et al. Does leptin play a role in the pathogenesis of human nonalcoholic steatohepatitis? Am J Gastroenterol 2003;98:2771-2776.
23. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? HEPATOLOGY 2004;40:46-54.
24. Bugianesi E, Pagotto U, Manini R, Vanni E, Gastaldelli A, de Iasio R, et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 2005;90:3498-3504.
25. Mizukoshi E, Rehermann B. Immune responses and immunity in hepatitis C virus infection. J Gastroenterol 2001;36:799-808.
26. Rosen HR. Hepatitis C pathogenesis: mechanisms of viral clearance and liver injury. Liver Transpl 2003;9(Suppl):S35-S43.
27. Knobler H, Zhornicky T, Sandler A, Haran N, Ashur Y, Schattner A. Tumor necrosis factor-alpha-induced insulin resistance may mediate the hepatitis C virus-diabetes association. Am J Gastroenterol 2003;98:2751-2756.
28. Hickman IJ, Powell EE, Prins JB, Clouston AD, Ash S, Purdie DM, et al. In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. J Hepatol 2003;39: 1042-1048.
29. Piche T, Vandenbos F, Abakar-Mahamat A, Vanbiervliet G, Barjoan EM, Calle G, et al. The severity of liver fibrosis is associated with high leptin levels in chronic hepatitis C. J Viral Hepat 2004;11:91-96.
30. Crespo J, Rivero M, Fabrega E, Cayon A, Amado JA, Garcia-Unzeta MT, et al. Plasma leptin and TNF-alpha levels in chronic hepatitis C patients and their relationship to hepatic fibrosis. Dig Dis Sci 2002;47: 1604-1610.
31. Maeno T, Okumura A, Ishikawa T, Kato K, Sakakibara F, Sato K, et al. Mechanisms of increased insulin resistance in non-cirrhotic patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol 2003;18: 1358-1363.
32. Zylberberg H, Rimaniol AC, Pol S, Masson A, De Groote D, Berthelot P, et al. Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity. J Hepatol 1999;30:185-191.
33. Oyanagi Y, Takahashi T, Matsui S, Takahashi S, Boku S, Takahashi K, et al. Enhanced expression of interleukin-6 in chronic hepatitis C. Liver 1999;19:464-472.
34. Malaguarnera M, Di Fazio I, Romeo MA, Restuccia S, Laurino A, Trovato BA. Elevation of interleukin 6 levels in patients with chronic hepatitis due to hepatitis C virus. J Gastroenterol 1997;32:211-215.
35. Giannini E, Ceppa P, Botta F, Mastracci L, Romagnoli P, Comino I, et al. Leptin has no role in determining severity of steatosis and fibrosis in patients with chronic hepatitis C. Am J Gastroenterol 2000;95:3211-3217.
36. Romero-Gomez M, Castellano-Megias VM, Grande L, Irles JA, Cruz M, Nogales MC, et al. Serum leptin levels correlate with hepatic steatosis in chronic hepatitis C. Am J Gastroenterol 2003;98:1135-1141.
37. Oncul O, Top C, Cavuplu T. Correlation of serum leptin levels with insulin sensitivity in patients with chronic hepatitis-C infection. Diabetes Care 2002;25:937.
38. Petit JM, Minello A, Jooste V, Bour JB, Galland F, Duvillard L, et al. Decreased plasma adiponectin concentrations are closely related to steatosis in hepatitis C virus-infected patients. J Clin Endocrinol Metab 2005; 90:2240-2243.
39. Lu JY, Chuang LM, Yang WS, Tai TY, Lai MY, Chen PJ, et al. Adiponectin levels among patients with chronic hepatitis B and C infections and in response to IFN-alpha therapy. Liver Int 2005;25:752-759.
40. Liu CJ, Chen PJ, Jeng YM, Huang WL, Yang WS, Lai MY, et al. Serum adiponectin correlates with viral characteristics but not histologic features in patients with chronic hepatitis C. J Hepatol 2005;43:235-242.
41. Jonsson JR, Moschen AR, Hickman IJ, Richardson MM, Kaser S, Clouston AD, et al. Adiponectin and its receptors in patients with chronic hepatitis C. J Hepatol 2005;43:929-936.
42. McTernan PG, McTernan CL, Chetty R, Jenner K, Fisher FM, Lauer MN, et al. Increased resistin gene and protein expression in human abdominal adipose tissue. J Clin Endocrinol Metab 2002;87:2407.
43. Nagaev I, Smith U. Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem Biophys Res Commun 2001;285:561-564.
44. Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV, et al. Resistin / Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 2001; 50:2199-2202.
45. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-1197.
46. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991;13:372-374.
47. Adinolfi LE, Utili R, Ruggiero G. Body composition and hepatic steatosis as precursors of fibrosis in chronic hepatitis C patients. HEPATOLOGY 1999; 30:1530-1531.
48. Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. HEPATOLOGY 2002;36:729-736.
49. Fartoux L, Poujol-Robert A, Guechot J, Wendum D, Poupon R, Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005;54:1003-1008.
50. Camma C, Bruno S, Di Marco V, Di Bona D, Rumi M, Vinci M, et al. Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. HEPATOLOGY 2006;43:64-71.